CLINICAL_TRIALS
trial_result
· 2011-02-09
Clinical Trial Update: A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty [Phase 3]
Summary
This update reports the completion of a Phase 3 trial evaluating two quarterly dosing regimens of leuprolide (11.25 mg and 30 mg) for central precocious puberty…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Abbott | Conditions: Puberty, Precocious | Phase 3 | Status: COMPLETED | Results posted: 2011-02-09